Orchid Pharma Future Growth
Future criteria checks 5/6
Orchid Pharma is forecast to grow earnings and revenue by 41.2% and 34.5% per annum respectively. EPS is expected to grow by 36% per annum. Return on equity is forecast to be 15.2% in 3 years.
Key information
41.2%
Earnings growth rate
36.0%
EPS growth rate
Pharmaceuticals earnings growth | 18.7% |
Revenue growth rate | 34.5% |
Future return on equity | 15.2% |
Analyst coverage | Low |
Last updated | 26 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2026 | 16,881 | 2,549 | 290 | N/A | 3 |
3/31/2025 | 10,780 | 1,422 | -1,907 | N/A | 3 |
3/31/2024 | 8,445 | 908 | -407 | N/A | 3 |
12/31/2023 | 8,122 | 1,246 | N/A | N/A | N/A |
9/30/2023 | 7,513 | 1,027 | 546 | 1,043 | N/A |
6/30/2023 | 7,178 | 775 | N/A | N/A | N/A |
3/31/2023 | 6,659 | 531 | -666 | 183 | N/A |
12/31/2022 | 6,341 | -175 | N/A | N/A | N/A |
9/30/2022 | 6,357 | -356 | 75 | 782 | N/A |
6/30/2022 | 5,982 | -471 | N/A | N/A | N/A |
3/31/2022 | 5,596 | -604 | 781 | 925 | N/A |
12/31/2021 | 5,010 | -592 | N/A | N/A | N/A |
9/30/2021 | 4,424 | -934 | 364 | 393 | N/A |
6/30/2021 | 4,232 | -1,009 | N/A | N/A | N/A |
3/31/2021 | 4,501 | -952 | 230 | 236 | N/A |
12/31/2020 | 4,420 | -1,307 | N/A | N/A | N/A |
9/30/2020 | 4,687 | -1,136 | N/A | N/A | N/A |
6/30/2020 | 4,918 | -1,153 | N/A | N/A | N/A |
3/31/2020 | 4,838 | -697 | 766 | 808 | N/A |
3/31/2019 | 6,000 | 694 | 54 | 120 | N/A |
3/31/2018 | 6,830 | -3,528 | 30 | 92 | N/A |
3/31/2017 | 7,965 | -4,954 | N/A | 4,010 | N/A |
3/31/2016 | 8,734 | -2,791 | N/A | 2,122 | N/A |
3/31/2015 | 11,644 | -1,311 | N/A | -2,460 | N/A |
9/30/2013 | 12,985 | -3,720 | N/A | 1,121 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 524372's forecast earnings growth (41.2% per year) is above the savings rate (6.7%).
Earnings vs Market: 524372's earnings (41.2% per year) are forecast to grow faster than the Indian market (17.3% per year).
High Growth Earnings: 524372's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 524372's revenue (34.5% per year) is forecast to grow faster than the Indian market (9.9% per year).
High Growth Revenue: 524372's revenue (34.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 524372's Return on Equity is forecast to be low in 3 years time (15.2%).